Total Voting Rights (6920E)
April 11 2011 - 9:54AM
UK Regulatory
TIDMHIK
RNS Number : 6920E
Hikma Pharmaceuticals Plc
11 April 2011
Hikma Pharmaceuticals PLC - Voting Rights and Capital
LONDON, 11 April 2011 Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) notifies the market that as at 31 March 2011 its
capital consists of 193,560,989 ordinary shares with voting rights.
There are no shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and
Transparency Rules.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders was $99 million (2009 $78
million). For news and other information, please visit
www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREADLFFSLFEFF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024